Best Life Sciences Companies in Burlingame, United States
The 32 best Life Sciences companies in Burlingame, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Color.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Burlingame
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Color 🦄 Provider of end-to-end Virtual clinic offering cancer-based solutions | $491M | 60 mo ago | 606 606 → 638 (+5%) | Elad Gil Co-Founder | Series E | 19 patents Peer-to-peer wireless content sharing and group formation within social networking platforms | — |
| 2 | ALX Oncology Developer of immuno-oncology therapies for cancer treatment | $123M | 80 mo ago | 59 | — | Public | 252 patents Immuno-oncology antibody‑drug conjugates targeting CD47/SIRPα and DNA‑damaging payloads | — |
| 3 | Igenica Develops antibody-based cancer medicines | $102M | 132 mo ago | 1 | — | Series C | 13 patents Therapeutic antibodies and antibody‑drug conjugates targeting CD98, C16orf54 for oncology | — |
| 4 | Corvus Pharmaceuticals Developer of therapeutics to treat cancers, immune disorders, and infectious diseases | $88M | 133 mo ago | 29 | — | Public | 175 patents Selective ITK kinase inhibitors for immune modulation and A2A receptor antagonists for neuro‑degenerative therapy | — |
| 5 | Tallac Therapeutics Provider of immune-therapy based treatment for oncology | $83M | 71 mo ago | 24 24 → 13 (-46%) | Hong Wan President | Series A | — | — |
| 6 | APT Pharmaceuticals Development for drugs for treatment of lung diseases | $62M | 217 mo ago | — | Stephen Dilly ex-CEO | Series B | — | — |
| 7 | NapaJen Pharma Developer of oligonucleotide therapeutics for immune diseases | $38M | 94 mo ago | 3 | Hironori Ando Co-Founder & CEO & President | Series C | — | — |
| 8 | Hinge Bio Develops antibodies for therapy and diagnosis | $36M | 21 mo ago | 10 10 → 20 (+100%) | Miriam Siekevitz Co-Founder & General Counsel & Chief Administrative Officer | Series A | — | — |
| 9 | Magnus Medical Provider of non invasive neuromodulation system for depression treatment | $25M | 21 mo ago | 11 | Brandon Bentzley Co-Founder | Series B | — | — |
| 10 | Halo Labs Developer of subvisible particle analyzer for life science and materials applications | $24M | 52 mo ago | 41 | — | Acquired | — | — |
| 11 | Protillion Provider of platform for protein analysis | $19M | 46 mo ago | 9 | Curtis Layton Founder & CEO | Series A | — | — |
| 12 | Collaborative Drug Discovery Biological and chemical database to manage private and external data | $16M | 67 mo ago | 31 | Barry Bunin CEO & President | Series A | — | — |
| 13 | Epitomics Life science reagents: antibodies, proteins, kits, and expert scientific support | $16M | 213 mo ago | — | Weimin Zhu Co-Founder | Acquired | 86 patents Monoclonal antibody discovery, engineering, and anti‑VEGF therapeutic production platforms | — |
| 14 | Iolyx Therapeutics Developer of therapeutics for autoimmunity and ophthalmological conditions | $15M | 11 mo ago | — | Elizabeth Jeffords CEO & President | Series B | — | — |
| 15 | Redwood Bioscience Biosciences: E. coli recombinant proteins, ELISA kits, antibody innovation | $12M | 151 mo ago | 5 | — | Acquired | 97 patents Patents concentrated in chemistry & materials | — |
| 16 | Pulse Biosciences Developer of a platform technology called Nano-Pulse Electro-Signaling | $8M | 42 mo ago | 61 61 → 118 (+93%) | Burke Barrett President & Chief Executive Officer | Acquired | 350 patents Pulsed electric field medical ablation catheters for electroporation-based tissue treatment | — |
| 17 | Origen Therapeutics Develops human polyclonal antibodies from avian transgenic animal technology | $4M | 194 mo ago | — | — | Deadpooled | — | — |
| 18 | GeneLancet Biosciences Developer of gene editing technology | $600K | 19 mo ago | 3 | — | Funding Raised | — | — |
Top 12 Life Sciences companies in Burlingame
#1
Series B · Burlingame, California · founded 2019$15Mraised▾
Developer of therapeutics for autoimmunity and ophthalmological conditions. The company utilizes proprietary pathways and tailored formulations for precise delivery to relevant tissues. The company's product line include ILYX-002 for ocular complications of autoimmune diseases and ILYX-004 for retinal indications.
- Dec 2025Series B$15M
#2
Series A · Burlingame, California · founded 2015 · 10 employees$36.2Mraised▾
Hinge Bio has developed a proprietary technology called Flex-Hinge for antibody development and antibody-like molecules with flexible and extendible non‐peptidyl hinges that allow for cooperative two or multiple handed binding. The company claims that these antibodies have enhanced specificity and efficacy for its target.
- Jan 2025Series A$30M
- Feb 2021Series A$18M
- Apr 2020Series A$18.2M
- Jun 2018Grant (prize money)$224.5K
#3
Series B · Burlingame, California · founded 2017 · 11 employees$25Mraised▾
Provider of non invasive neuromodulation system for depression treatment. It offers SAINT which is ad, MRI guided neuromodulation system that offers a rapid acting, non invasive treatment for major depressive disorder for patients who have not responded to traditional antidepressant therapies.
- May 2025Series B$23.7M
- Feb 2025Series B$40.3M
- Oct 2021Series A$25M
#4
Color 🦄Series E · Burlingame, California · founded 2013 · 606 employees$491.4Mraised▾
Provider of end-to-end Virtual clinic offering cancer-based solutions. It assesses cancer risk, increases screening accessibility, and accelerates diagnosis. It guides patients through treatment and provides support for survivors. It offers direct care through an in house care team, including oncologists, primary care physicians, genetic counselors, and oncology-trained care advocates. It integrates with health plans and existing benefits ecosystems.
- Oct 2021Series E$100M
- Dec 2020Series D$167M
- Jan 2020Series D$75M
- Aug 2019Grant (prize money)$4.6M
#5
Funding Raised · Burlingame, California · founded 2019 · 3 employees$600Kraised▾
GeneLancet Biosciences is a developer of gene-editing technology. The company has developed a patented gene-editing technology based on editing enzymes engineering, chemically modified guide RNAs, and cell targeting delivery. It also offers CRISPR-Cas libraries for drug discovery and CRISPR-Cas-lgRNA conjugates as molecular therapeutics.
- Mar 2025Grant (prize money)$300K
- Aug 2022Grant (prize money)$300K
#6
Acquired · Burlingame, California · founded 2010 · 41 employees$23.7Mraised▾
Halo Labs is a developer of precision scientific instrumentation with a focus on commercializing analytical technologies that enable high-throughput bio-analytical applications using optics, image processing, and microfluidics. The company's flagship product is the Horizon system - an optical analyzer for the quantitative analysis of sub-visible particles in early stages of formulation. The system allows low-volume, high-throughput analysis to obtain insights into stability and possible contamination.
- Jul 2022Series C$6M
- Apr 2020Series B$12M
- Dec 2018Series B$5.6M
- Jul 2018Series A—
#7
Public · Burlingame, California · founded 2015 · 59 employees$123Mraised▾
Developer of immuno-oncology therapies for cancer treatment. The lead product candidate ALX148 is a checkpoint inhibitor that comprises an affinity CD47 binding domain of SIRPα linked to an inactive Fc region of a human immunoglobulin. It binds CD47 and inhibits the CD47-SIRPα signaling pathway.
- Feb 2020Series C$105M
- May 2015Series A$18M
#8
Series A · Burlingame, California · founded 2020 · 24 employees$83.2Mraised▾
Tallac Therapeutics provides immune-therapy-based treatment for oncology. The novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform enables systemic delivery of targeted TLR9 agonist (T-CpG) for immune activation. The platform develops targeted immune therapies include TAC-001, ALTA-002 TIA for solid tumors.
- Dec 2020Series A$62M
- Jul 2020Series A$21.2M
#9
Series A · Burlingame, California · founded 2018 · 9 employees$19Mraised▾
Provider of platform for protein analysis. Biologics (e.g. protein drugs) direct protein analysis techniques lag well behind DNA sequencing methods in throughput and automation, making the identification of new protein drug candidates.
- Dec 2022Series A$19M
- May 2020Grant (prize money)$2M
#10
Series C · Burlingame, California · founded 2009 · 1 employees$101.8Mraised▾
Develops antibody-based cancer medicines. Igenica contends that the key to next-generation mAb-based medicines lies in both the identification of new targets and the deployment of novel antibody discovery approaches. The company has developed two unique technology platforms that collectively offer a function-orientated screening strategy to systematically identify new tumor antigens and effective mAb drug candidates.
- Oct 2015Series C$2.3M
- Jun 2015Series C$1.2M
- Jan 2015Series C$5.1M
- Aug 2014Grant (prize money)$215.7K
#11
Acquired · Burlingame, California · founded 2014 · 61 employees$8Mraised▾
Developer of a platform technology called Nano-Pulse Electro-Signaling. The NPES pulses are applied directly to tissues, creating a transient opening of small pores in cell and organelle membranes. By controlling this disruption of the cellular organelles, cellular response can be directed quite specifically. It can be used for the treatment of cancer by triggering a signalling cascade within the tumor cells.
- May 2023Post IPO$65M
- Sep 2017Post IPO$30M
- Feb 2017Post IPO$5M
- Nov 2014Series A$8M
#12
Public · Burlingame, California · founded 2014 · 29 employees$87.7Mraised▾
Developer of therapeutics to treat cancers, immune disorders, and infectious diseases. The company focuses to design medicines with differentiated mechanisms of action, targeting critical cellular elements of the immune system such as B cells and T cells. The company has a pipeline of five proprietary agents with differentiated mechanisms of action.
- Sep 2015Series B$75M
- Dec 2014Series A$12.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.